Ambrose Healthcare Licenses AM-Pharma's Sepsis Drug recAP for $181 Million
Start here
Ambrose Healthcare has licensed recombinant human alkaline phosphatase (recAP) from AM-Pharma for $181 million, gaining rights to the experimental treatment for sepsis-associated acute kidney injury. The deal, signed October 20, 2026, marks another change of ownership for an asset with a turbulent history: in 2015, Pfizer offered roughly 430 million euros to acquire recAP outright, but AM-Pharma's shareholders rejected the bid. The licensing agreement now returns the drug to late-stage commercial development under a new sponsor. Open questions include the terms beyond the headline fee, the development timeline Ambrose will pursue, and whether recAP can finally deliver on the promise that once attracted one of the world's largest pharmaceutical companies.
Written by a model from the reports · updated 3 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- WeChatPickAmbrose Healthcare Licenses AM-Pharma Sepsis Drug recAP for $181 Million
Ambrose Healthcare has licensed recombinant human alkaline phosphatase (recAP) from AM-Pharma for $181 million to treat sepsis-associated acute kidney injury. In 2015, Pfizer offered about 430 million euros to acquire the asset, but AM-Pharma shareholders rejected the bid. The deal, signed October 20, marks another change of ownership for recAP.
Coverage and heat for this story
Reports so far 2·Heat now 12·Peak heat 16 (Oct 21 09:00)·Reports, 24h +1
Two panels, same clock (pointer stays in sync): top is cumulative editorial reports — only rises; last point = All reports; slope = new reports that hour. Bottom is Live-board heatIndex — 7-day participants with a 24-hour half-life, so it can fall when talk cools.